A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)

LESSONS LEARNED. Dual epidermal growth factor receptor (EGFR)‐directed therapy with erlotinib and panitumumab in combination with gemcitabine was superior to gemcitabine and erlotinib, but the clinical relevance is uncertain given the limited role of gemcitabine monotherapy. A significantly longer o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Halfdanarson, Thorvardur R., Foster, Nathan R., Kim, George P., Meyers, Jeffrey P., Smyrk, Thomas C., McCullough, Ann E., Ames, Matthew M., Jaffe, Jeffrry P., Alberts, Steven R.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2019
Schlagworte:
Clinical Trial Results
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6516109/
https://ncbi.nlm.nih.gov/pubmed/30679315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0878
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge